雲智匯科技(01037.HK)復牌曾漲近1.3倍 附屬與優必選(09880.HK)合作推銷人形機器人
雲智匯科技(01037.HK)今早(23日)復牌後高開45.16%,其後升幅曾擴大至1.29倍,高見1.42元創2018年6月以來逾七年高。現報1.19元,升91.94%,成交5,757.2萬股,涉資6,903.26萬元。
公司公布全資附屬雲智匯深圳與優必選(09880.HK)訂立潛在戰略合作的諒解備忘錄,據此,雲智匯深圳將負責人形機器人產品的全球銷售、營銷及售後服務,而優必選則負責有關產品的研發、製造及技術支持。聲明強調,備忘錄項下擬進行的交易可能進行或可能不進行。該股今早復牌。
該股昨日(22日)上午10時32分中途停牌,停牌前報0.62元,升1.34倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.